ProQR Therapeutics N.V. received a Schedule 13G filing from several Dutch investment entities and portfolio manager Patrick Johan Hendrik Krol, disclosing passive ownership positions in the company’s ordinary shares.
Aescap Life Sciences reports beneficial ownership of approximately 3.9% of ProQR’s ordinary shares, while Privium Fund Management B.V., as fund manager of Aescap Life Sciences and Aescap Genetics, reports beneficial ownership of about 5.2%. Aescap Genetics holds around 1.2% and Inspirational Visions about 0.1% of the outstanding shares. Krol, through his roles with these entities and his own holdings, may be deemed to beneficially own approximately 5.2% of the shares.
The percentages are based on 105,345,192 ordinary shares outstanding as of September 30, 2025. The filing certifies that the securities were not acquired for the purpose of changing or influencing control of ProQR and are held on a passive basis.
Positive
None.
Negative
None.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
ProQR Therapeutics N.V.
(Name of Issuer)
Ordinary Shares, nominal value EUR0.04 per share
(Title of Class of Securities)
N71542109
(CUSIP Number)
12/11/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
N71542109
1
Names of Reporting Persons
STICHTING AESCAP LIFE SCIENCES
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
NETHERLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
4,156,878.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
4,156,878.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,156,878.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.9 %
12
Type of Reporting Person (See Instructions)
FI
Comment for Type of Reporting Person: (1) Based upon 105,345,192 ordinary shares outstanding as of September 30, 2025, as disclosed in the Issuer's Report of Foreign Private Issuer on Form 6-K filed on November 6, 2025.
SCHEDULE 13G
CUSIP No.
N71542109
1
Names of Reporting Persons
PRIVIUM FUND MANAGEMENT B.V.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
NETHERLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
5,467,149.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
5,467,149.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,467,149.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.2 %
12
Type of Reporting Person (See Instructions)
FI
Comment for Type of Reporting Person: (1) Based upon 105,345,192 ordinary shares outstanding as of September 30, 2025, as disclosed in the Issuer's Report of Foreign Private Issuer on Form 6-K filed on November 6, 2025.
SCHEDULE 13G
CUSIP No.
N71542109
1
Names of Reporting Persons
STICHTING AESCAP GENETICS
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
NETHERLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
1,310,271.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
1,310,271.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,310,271.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.2 %
12
Type of Reporting Person (See Instructions)
FI
Comment for Type of Reporting Person: (1) Based upon 105,345,192 ordinary shares outstanding as of September 30, 2025, as disclosed in the Issuer's Report of Foreign Private Issuer on Form 6-K filed on November 6, 2025.
SCHEDULE 13G
CUSIP No.
N71542109
1
Names of Reporting Persons
INSPIRATIONAL VISIONS B.V.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
NETHERLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
35,411.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
35,411.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
35,411.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.1 %
12
Type of Reporting Person (See Instructions)
FI
Comment for Type of Reporting Person: (1) Based upon 105,345,192 ordinary shares outstanding as of September 30, 2025, as disclosed in the Issuer's Report of Foreign Private Issuer on Form 6-K filed on November 6, 2025.
SCHEDULE 13G
CUSIP No.
N71542109
1
Names of Reporting Persons
PATRICK JOHAN HENDRIK KROL
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
NETHERLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
5,528,862.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
5,528,862.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,528,862.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.2 %
12
Type of Reporting Person (See Instructions)
FI
Comment for Type of Reporting Person: (1) Based upon 105,345,192 ordinary shares outstanding as of September 30, 2025, as disclosed in the Issuer's Report of Foreign Private Issuer on Form 6-K filed on November 6, 2025.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
ProQR Therapeutics N.V.
(b)
Address of issuer's principal executive offices:
Zernikedreef 9 Leiden, The Netherlands, CK 2333
Item 2.
(a)
Name of person filing:
(i) Stichting Aescap Life Sciences ("Aescap Life Sciences")
(ii) Privium Fund Management B.V. ("Privium"), as the fund manager of Aescap Life Sciences
(iii) Stichting Aescap Genetics ("Aescap Genetics")
(iv) Inspirational Visions BV ("Inspirational Visions")
(v) Patrick Johan Hendrik Krol ("Krol"), the portfolio manager for Privium regarding Aescap Life Sciences and Aescap Genetics and the managing director of Inspirational Visions
The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
(b)
Address or principal business office or, if none, residence:
The principal business address of each of Aescap Life Sciences, Privium, Aescap Genetics and Krol is:
Gustav Mahlerplein 3
1082 MS Amsterdam
The Netherlands
The principal business address of Inspirational Visions is:
A.J. Ernststraat 595-C
1082 LN Amsterdam
The Netherlands
(c)
Citizenship:
The citizenship of each of the Reporting Persons is the Netherlands.
(d)
Title of class of securities:
Ordinary Shares, nominal value EUR0.04 per share
(e)
CUSIP No.:
N71542109
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
As its Fund Manager, the Shares held by Aescap Life Sciences may be deemed to be beneficially owned by Privium. In addition, as its Fund Manager, the Shares held by Aescap Genetics may be deemed to be beneficially owned by Privium. As the portfolio manager of Privium, Krol may be deemed to beneficially own the Shares held by Aescap Life Sciences and Aescap Genetics. In addition, as the managing director of Inspirational Visions, Krol may be deemed to beneficially own the Shares held by Inspirational Visions.
As of the date of this report, Aescap Life Sciences directly held 4,156,878 Shares. As of the date of this report, Aescap Genetics directly held 1,310,271 Shares. As of the date of this report, Inspirational Visions directly held 35,411 Shares. As of the date of this report, Krol directly held 26,302 Shares.
(b)
Percent of class:
Aescap Life Sciences may be deemed the beneficial owner of approximately 3.9% of the Shares outstanding.
Privium may be deemed the beneficial owner of approximately 5.2% of the Shares outstanding.
Aescap Genetics may be deemed the beneficial owner of approximately 1.2% of the Shares outstanding.
Inspirational Visions may be deemed the beneficial owner of approximately 0.1% of the Shares outstanding.
Krol may be deemed the beneficial owner of approximately 5.2% of the Shares outstanding.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
STICHTING AESCAP LIFE SCIENCES
Signature:
/s/ P.J.H. Krol
Name/Title:
P.J.H. Krol, Portfolio Manager of Privium Fund Management B.V., its Fund Manager
Date:
01/20/2026
PRIVIUM FUND MANAGEMENT B.V.
Signature:
/s/ P.J.H. Krol
Name/Title:
P.J.H. Krol, Portfolio Manager
Date:
01/20/2026
STICHTING AESCAP GENETICS
Signature:
/s/ P.J.H. Krol
Name/Title:
P.J.H. Krol, Portfolio Manager of Privium Fund Management B.V., its Fund Manager
What stake in ProQR (PRQR) is reported in this Schedule 13G?
The filing shows Dutch investment entities and portfolio manager Patrick Johan Hendrik Krol may be deemed to beneficially own up to approximately 5.2% of ProQR’s ordinary shares, based on the reported relationships and holdings.
How many ProQR shares do the reporting persons collectively reference?
The filing reports Aescap Life Sciences directly holding 4,156,878 shares, Aescap Genetics 1,310,271 shares, and Inspirational Visions 35,411 shares, with Krol also directly holding 26,302 shares and Privium Fund Management B.V. deemed to beneficially own 5,467,149 shares.
What percentage of ProQR (PRQR) does each key reporting entity hold?
Aescap Life Sciences is listed at approximately 3.9% of the outstanding shares, Privium Fund Management B.V. at about 5.2%, Aescap Genetics at about 1.2%, Inspirational Visions at about 0.1%, and Krol may be deemed to beneficially own approximately 5.2%.
On what share count are the ProQR ownership percentages based?
All reported ownership percentages are based on 105,345,192 ordinary shares outstanding as of September 30, 2025, as referenced from ProQR’s Form 6-K dated November 6, 2025.
Are the ProQR (PRQR) shares held for control purposes?
No. The certification states that the securities were not acquired and are not held for the purpose of changing or influencing control of ProQR and are not held in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
Who are the reporting persons named in the ProQR Schedule 13G?
The reporting persons are Stichting Aescap Life Sciences, Privium Fund Management B.V., Stichting Aescap Genetics, Inspirational Visions B.V., and Patrick Johan Hendrik Krol, all with citizenship in the Netherlands.
What type of investors are the ProQR Schedule 13G filers classified as?
Each reporting person is classified under the type code FI (financial institution) for purposes of the Schedule 13G.
